PRF1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1061129	1.00	20/20
SCHEMBL1061131	1.00	20/20
SCHEMBL2015450	1.00	20/20
SCHEMBL2015453	1.00	20/20
SCHEMBL2019750	1.00	20/20
SCHEMBL2020178	1.00	20/20
SCHEMBL2020179	1.00	20/20
SCHEMBL2037184	1.00	20/20
SCHEMBL2037186	1.00	20/20
SCHEMBL2038593	1.00	20/20
SCHEMBL2038596	1.00	20/20
SCHEMBL2038597	1.00	20/20
SCHEMBL2039235	1.00	20/20
SCHEMBL2039236	1.00	20/20
SCHEMBL2039969	1.00	20/20
SCHEMBL2040195	1.00	20/20
SCHEMBL2040200	1.00	20/20
SCHEMBL2042894	1.00	20/20
SCHEMBL2042898	1.00	20/20
SCHEMBL2042927	1.00	20/20

Clinical trials — most relevant to PRF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Latency in Pulmonary Tuberculosis	PHASE3	COMPLETED
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer	PHASE2/PHASE3	UNKNOWN
BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots	PHASE3	COMPLETED
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD	PHASE1/PHASE2	COMPLETED
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia	PHASE2	RECRUITING
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor	PHASE1/PHASE2	RECRUITING
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer	PHASE2	COMPLETED
A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia	PHASE2	NOT_YET_RECRUITING
Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer	PHASE1	COMPLETED
Expansion of Virus-Specific Lymphocytes for Cell Therapy	PHASE1	RECRUITING
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer	PHASE1	COMPLETED
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis	nan	UNKNOWN
Children and Adult Hemophagocytic Syndrome (HLHa)	nan	COMPLETED
Immunomodulatory and Preventive Effects of Olive Leaf Tea Against COVID-19	nan	COMPLETED
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura	nan	UNKNOWN
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients	nan	RECRUITING
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy	nan	COMPLETED
Granzymes and Perforin at the Onset of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations	nan	COMPLETED
Observation on the Treg in the Uveitis Patients	nan	COMPLETED
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer	nan	COMPLETED
Cellular Immunity and Renal Cell Cancer	nan	COMPLETED
Genetic Analysis of Psoriasis and Psoriatic Arthritis	nan	COMPLETED
Investigation of the Effects of H-PRF on the Period After Impacted Third Molar Tooth Extraction	nan	COMPLETED
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence	nan	UNKNOWN
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being	nan	UNKNOWN
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)	nan	UNKNOWN
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function	nan	UNKNOWN
Comorbidities and Coinfections in Latent TB	nan	UNKNOWN
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PRF1 binder may also engage these)

Protein	Name	Similarity
P10820	—	1.000	P10820 →
P35763	—	0.996	P35763 →
Q2KJC3	—	0.985	Q2KJC3 →
Q9DBX3	—	0.984	Q9DBX3 →
Q9UGT4	—	0.984	Q9UGT4 →
AOC3	Amine oxidase [copper-containing] 3	0.979	landscape →
Q0V8J4	—	0.979	Q0V8J4 →
Q9JHA8	—	0.978	Q9JHA8 →
ITGB7	Integrin beta-7	0.978	landscape →
AOC1	Diamine oxidase [copper-containing]	0.978	landscape →
A0A286YEC0	—	0.978	A0A286YEC0 →
Q6MG64	—	0.977	Q6MG64 →
P79263	—	0.977	P79263 →
Q9ER38	—	0.977	Q9ER38 →
O70423	—	0.976	O70423 →
LOXL3	Lysyl oxidase homolog 3	0.976	landscape →
P02702	—	0.976	P02702 →
Q5EA85	—	0.976	Q5EA85 →
Q9H497	—	0.976	Q9H497 →
P0C0K7	—	0.976	P0C0K7 →
O95897	—	0.976	O95897 →
Q8IVN8	—	0.976	Q8IVN8 →
P0C0K6	—	0.976	P0C0K6 →
Q9Y334	—	0.975	Q9Y334 →
Q3U435	—	0.975	Q3U435 →
INSRR	Insulin receptor-related protein	0.975	landscape →
Q9WTL4	—	0.975	Q9WTL4 →
Q96PQ0	—	0.975	Q96PQ0 →
Q62190	—	0.975	Q62190 →
Q9WV57	—	0.975	Q9WV57 →